ZNF287

Across TCGA pan-cancer cohorts, ZNF287 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of ZNF287’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where ZNF287 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ZNF287 is over-expressed in tumor, although a few such as LUAD and LSCC show the opposite, repressed pattern.

HNSC, LUAD, and LSCC are the cancer types where ZNF287 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ZNF287 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	+0.455	<.001	11	view →
LUAD	Male	III,IV	−1.095	<.001	9	view →
LSCC	Male	II,III,IV	−1.257	<.001	8	view →
COAD	All	II,III,IV	−0.357	<.001	8	view →
PDAC	Male	All	+0.930	<.001	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

ZNF287–HNSC

Open the HNSC breakdown →